Shortening the timeline for clinical drug developments

Building international collaborations and the WINTHER trial

GFI is crucial for AML1-ETO induced acute myeloid leukemia

Signaling and targeting cellular pathways in leukaemia metabolism

Whole genome sequence analysis for acute lymphoblastic leukaemia

Use of mesenchymal stromal cells against graft-versus-host disease

Next generation sequencing and the monoclonal structure of multiple myeloma

Mouse models and proteomics tackling acute lymphoblastic leukaemia

How malignant cells in patients with CLL escape T-cell recognition

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy

MEK inhibitor, trametinib, improves progression free survival in melanoma

Drug development in small cell and non-small cell lung cancer